What were the focus areas for Palantir's analysis?

The report focused on Palantir's data analytics and AI capabilities, government contracts, and commercial expansion.

Does the report give a buy or sell recommendation?

No, the report provides a neutral analysis without buy or sell recommendations.

Zacks Highlights Palantir, Eli Lilly, and HSBC in Top Stock Report

Zacks released its weekly top stock report, featuring analysis of Palantir Technologies, Eli Lilly, and HSBC, focusing on growth drivers, opportunities, and key risks.

July 6, 2026

2 min read

Source: Zacks

Zacks has released its weekly top stock report, featuring detailed analysis of Palantir Technologies (PLTR), Eli Lilly (LLY), and HSBC, highlighting growth drivers, opportunities, and key risks shaping each company's outlook.

Key Highlights

Palantir (PLTR): The report emphasized the company's data analytics and AI capabilities, noting government contracts and commercial expansion as key growth drivers.
Eli Lilly (LLY): Focus was on the company's leading diabetes and obesity drugs, such as Mounjaro and Zepbound, and their revenue impact.
HSBC: The report discussed the bank's Asia-focused strategy and capital markets business, highlighting loan growth and higher interest rates.

Context

The report comes amid market volatility driven by economic data and interest rate expectations. These stocks are among the most actively traded in their sectors.

What It Means for Investors

The report provides a neutral overview of these companies without offering buy or sell recommendations. Investors can use it as a starting point for further research and analysis.

Frequently Asked Questions

The report included Palantir Technologies (PLTR), Eli Lilly (LLY), and HSBC.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.